The imminent end of the rebate era means human resources (HR) benefits decision-makers and pharmacy consultants are about to see a paradigm shift. They will need to act quickly to adjust benefits ...
Four GOP members of the House of Representatives joined with House Democrats to force a vote on extending tax credits that ...
In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals ...
Harbour BioMed announced it has entered a multi-year, global strategic collaboration and license agreement with Bristol Myers ...
The drop reflects investors reactions to Pfizer’s new 2026 revenue forecasts, which is set to be between the range of $59.5 billion to $62.5 billion, a decline of $1.5 billion from 2025’s estimated ...
The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance therapy for adolescents and adults with severe asthma characterized by an eosinophilic phenotype. 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results